arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Viridian Therapeutics, Inc.DE

VRDN
$28.52 ▼ -0.54 (-1.84%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
13 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
15
Health
Poor
Bearish
auto_awesome

Analytical Summary

Viridian Therapeutics, Inc.DE faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap —
Dividend Yield —
Revenue Growth 23359.9% ↗
Op. Margin None
ROIC -39.8% ↘
FCF / Share None
Trailing P/E —
Price / Book 4.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

13-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$70.85M
↑ +23359.9% —
Net Income Profit after all expenses
$-342.60M
↓ -26.9% —
Operating Margin Operating profit as % of sales
-394.5%
↑ +19.2% —
FCF / Share Free cash flow per share
$-4.14
↓ -40.2% —
Long-Term Debt Long-term obligations
$20.58M
↑ +1.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
0
Returns ↓
17
Financial Health ↑
10
Cash Quality ↑
54

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 13 years · 54 quarters